TOKYO–(BUSINESS WIRE)–Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).
Solasia Pharma K.K.
Toyokazu Ohata, Public Relations and Investor Relations
Tel: +81 3 5843 8046 (TOKYO)
info@solasia.co.jp
HONG KONG SAR - Media OutReach Newswire - 5 February 2026 - The national "15th…
BANGKOK, THAILAND - Media OutReach Newswire - 5 February 2026 - K-pop star G?Dragon's first…
SonicWall Proudly Honours 113 Global Partners Recognized for Driving Innovation, Fueling Growth and Delivering Cybersecurity…
HONG KONG SAR - Media OutReach Newswire - 5 February 2026 - The Hong Kong…
Key business indicators significantly surpass industry average Firmly ranks among the top five pan-Asian insurers…
New AI and cloud technologies support smarter, faster, and more efficient Olympic broadcasting worldwide Alibaba's…
